Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878869 | 1.00 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL283340 | 1.00 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL7063746 | 0.86 | CYP2D6 (0.48) | CYP2D6 | |
| SCHEMBL11751768 | 0.80 | PKM (0.41) | — | |
| SCHEMBL22851451 | 0.80 | THRB (0.42) | — | |
| SCHEMBL11383973 | 0.80 | LMNA (0.36) | — | |
| SCHEMBL2245340 | 0.79 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL21587527 | 0.78 | ADRB3 (0.40) | — | |
| SCHEMBL4147093 | 0.78 | ALDH1A1 (0.35) | — | |
| SCHEMBL24192869 | 0.77 | CYP2D6 (0.43) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111021089-B | Super-fiber bass full-water filling method | 温州大学 | 2022-12-06 | — | — | CN | claimed |
| US-20080193873-A1 | CHANGING LIGHT ABSORPTION BY DISRUPTION OF CONJUGATION | VERIFICATION TECHNOLOGIES, INC. (US) | 2008-08-14 | — | — | US | claimed |
| US-20070202290-A1 | DATA-PROTECTED DIGITAL RECORDING MEDIA | VERIFICATION TECHNOLOGIES, INC. (US) | 2007-08-30 | — | — | US | claimed |
| EP-1810290-A2 | CHANGING LIGHT ABSORPTION BY DISRUPTION OF CONJUGATION | Verification Technologies, Inc (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1726008-A2 | BIS-PROPYLAMINE ANALOG AND COMPOSITION | Verificatin Technologies, Inc (US) | 2006-11-29 | — | — | EP | claimed |
| US-20060078707-A1 | Changing light absorption by disruption of conjugation | SPENCER TRASK HEALTHCARE VENTURES LLC | 2006-04-13 | — | — | US | claimed |
| WO-2006036885-A2 | CHANGING LIGHT ABSORPTION BY DISRUPTION OF CONJUGATION | VERIFICATION TECHNOLOGIES, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2005098842-A2 | BIS-PROPYLAMINE ANALOG AND COMPOSITION | VERIFICATION TECHNOLOGIES, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20040152017-A1 | Bis-propyl amine analog and composition | VIG RAKESH (US) | 2004-08-05 | — | — | US | claimed |
| WO-1998007653-A1 | CHIRAL HYDRIDE COMPLEXES | ZEELAND CHEMICALS, INC. (US) | 1998-02-26 | — | — | WO | claimed |
| US-3962338-A | Novel methods and compounds employed therein | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | claimed |
| CN-117466835-A | Preparation method of 3-thiotimolol maleate | 承德医学院 | 2024-01-30 | — | — | CN | disclosed |
| CN-220091442-U | Quick water separator | 上海科利生物医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11578054-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-14 | — | — | US | disclosed |
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| US-4097490-A | Pyroglutamic acid salts of t-butylamino-2,3-dihydroxypropane | MERCK & CO., INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4051144-A | ADRENERGIC BLOCKING AGENTS | CHARLES E. FROSST & CO. (CA) | 1977-09-27 | — | — | US | disclosed |
| US-4031125-A | 3-Sulfonate ester of 2,3-dihydroxypropylamine | MERCK & CO., INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-3998835-A | HYPERLIPOIDEMIA AND HYPERGLYCEMIA INHIBITORS, ANTIARRYHTHMIC AGENTS | SANDOZ LTD. (CH) | 1976-12-21 | — | — | US | disclosed |
| US-3962338-A | Novel methods and compounds employed therein | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578054-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | CYP2D6 1989/4885 |
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | CYP2D6 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.